Price (delayed)
$159.73
Market cap
$34.96B
P/E Ratio
36.97
Dividend/share
N/A
EPS
$4.32
Enterprise value
$35.46B
Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome and paroxysmal nocturnal
There are no recent dividends present for ALXN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.